Alzheimer's disease (AD) isaprogressive neurodegenerative disorder characterized by chronic inflammation due to the presence of neurotoxic Aβ and tau proteins. Increased microglial activation and inflated immune response are the other factors to be considered in AD pathology. Microglial cells own biochemical machinery that synthesizes and release endocannabinoids. The exploitation of therapeutic actions of endocannabinoid system has newly emerged in the field of Alzheimer's disease. The activation of cannabinoid receptors/ cannabinoid system modulates inflammatory responses. This review assesses the association between the microglial endocannabinoid system and neuroinflammation in AD. The data supporting the anti-inflammatory role of pharmacological agents modulating cannabinoid system are also reviewed.

阿尔茨海默病 (AD) 是一种进行性神经退行性疾病，其特征是由于存在神经毒性 Aβ 和 tau 蛋白而导致的慢性炎症。增加的小胶质细胞活化和膨胀的免疫反应是 AD 病理学中要考虑的其他因素。小胶质细胞拥有合成和释放内源性大麻素的生化机制。内源性大麻素系统治疗作用的开发在阿尔茨海默病领域新出现。大麻素受体/大麻素系统的激活调节炎症反应。本综述评估了 AD 中小胶质细胞内源性大麻素系统与神经炎症之间的关联。还审查了支持调节大麻素系统的药物的抗炎作用的数据。